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Sirs: We present 2 cases of CNS disease associated with Sjögren's Syndrome (SjS) with 
anti aquaporin-4 water channel autoantibodies (AQP4-Ab) that were treated successfully 
with tacrolimus. Tacrolimus is an immunosuppressant that acts as a calcineurin inhibitor 
and suppresses Th2 cells [1].  Tacrolimus may also act as a neuroprotectant by reducing 
axonal and myelin damage, as shown in a mouse model of experimental autoimmune 
encephalomyelitis [2].  SjS is a chronic autoimmune disease characterized by 
lymphocytic infiltration of the exocrine glands. SjS-associated inflammation sometimes 
spreads into the CNS (CNS-SjS), occasionally mimics relapsing-remitting multiple 
sclerosis (MS), and inflammation often involves the brain, spinal cord, and optic nerve 
[3].  Neuromyelitis optica (NMO) is also a relapsing inflammatory disease of the CNS, 
characterized by severe attacks of optic nerve neuritis and longitudinally extensive 
transverse myelitis [4].  NMO is distinguished from MS by the presence of AQP4-Ab 
and differences in the distribution of inflammatory lesions and pathological findings.  
Combination therapy with a corticosteroid and azathioprine is the current standard 
treatment for preventing NMO relapse [5]; however, some patients are refractory to it.  
Approximately 3% of patients with NMO have coexisting SLE or SjS, and CNS-SjS 
patients with optic nerve neuritis or longitudinal myelitis (conditions called “NMO 
spectrum disorder”) often present positive for AQP4-Ab [4,6,7].  To our knowledge, this 
is the first reported assessment of tacrolimus in patients with CNS-SjS with AQP4-Ab. 
This treatment was approved by the ethical committee of our university, and the patients 
provided written informed consent. 
   A 48-year-old female (Case 1, Figure) was admitted with rapidly progressive nausea, 
hiccups, dysphagia, and drowsiness.  MRI revealed T2 hyperintensities of the 
3 
 
hypothalamus bilaterally and of the dorsal medulla oblongata.  After 3 courses of 
intravenous high-dose methylprednisolone (IHMP, 1 g/day for 3 days in 1 course), she 
recovered completely, except for mild dysphagia. One year after the first attack, she 
developed limb weakness. Laboratory tests revealed high levels of anti-RO (SS-A) 
antibodies and positive antinuclear antibody.  The Schirmer test and the Saxon test 
revealed decreased salivary secretion (Table).  She was diagnosed with CNS-SjS [8]. 
She experienced 9 attacks during the entire disease course, and we started treatment with 
oral tacrolimus during her 9th admission.  No recurrent attacks have been observed for 
49 months since the start of this treatment. 
   A 50-year-old female (Case 2) visited our hospital with acute left visual loss and 
depression.  She was diagnosed with retrobulbar optic nerve neuritis, but she rejected 
steroid therapy and was not admitted to our hospital.  One year later, she was sent to our 
hospital by ambulance due to weakness. Physical examination revealed dysphagia, 
dysarthria, incomplete tetraplegia, urinary retention, and depression. MRI revealed T2 
hyperintensities in the corpus callosum, thalamus, midbrain, and pons.  She was 
diagnosed with CNS-SjS based on SjS criteria (Table), and she was treated with IHMP.  
Because high doses of oral steroids may exacerbate depression, we started therapy with 
tacrolimus (3 mg/day) to prevent relapse.  No recurrence was observed for 9 months, but 
she could not continue the therapy due to exacerbation of depression. Two years after 
withdrawal, she suffered right hemiplegia, and MRI revealed a relapse lesion in the left 
posterior limb of the internal capsule. 
   The serum of both patients was positive for AQP4-Ab after the initiation of 
tacrolimus.  Because no recurrences were observed for at least 49 months (Case 1) and 9 
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months (Case 2), we concluded that tacrolimus is effective in CNS-SjS with AQP4-Ab. 
Considering the pathological observations that indicate loss of AQP4 with deposition of 
antibody and compliment in CNS lesions in NMO [9,10], we speculate that tacrolimus 
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Time course of relapse, therapies, symptoms, and images of Case 1.  Stars indicate 
attacks.  The thickness of each line represents the severity of any symptom or the dose 
of drug.  Nine attacks had occurred in spite of therapeutic approaches, and no attacks 
were observed after starting tacrolimus.  A: A sagittal fluid-attenuated inversion 
recovery (FLAIR)-weighted image at onset shows hyperintense lesions in the thalamus, 
the mammillary bodies and the dorsal portion of the medulla oblongata (arrows).  B: A 
photomicrograph of a labial salivary gland biopsy at the second admission.  An 
aggregate of lymphocytes surrounding a salivary gland.  Size bar is 50 µm.  C: A 
sagittal T2-weighted image at the fifth admission shows hyperintense lesions throughout 
the spinal cord (arrowheads).  
IHMP = Intravenous high-dose methylprednisolone (1 g/day for 3 days in 1 course); 
EDSS = Expanded Disability Status scale.  
Table.  Clinical Features of 2 Cases
Case 1 Case 2
Age at onset, sex 48, female 50, female
Ethnicity Japanese Japanese
Dry mouth + +
Number of relapses* 9 2
MRI findings
   Optic lesion + +
   Cerebral lesion + +
   Pontine lesion - +
   Medullary lesion + -
   Longitudinal cord lesion + -
Autoantibodies
   ANA + +
   SS-A + +
   SS-B - +
   Aquaporin-4 + +
Diagnostic tests for SjS
   Schirmer test + +
   Saxon test + +
   Salivary gland biopsy compatible for SjS not done
   Sialography not done compatible for SjS
CSF findings
   Cells /µl 26 37
   MBP [mg/dl, <4.0] 6.2 56.3
   Oligoclonal IgG bands - -
Diagnosis
   Criteria of SjS fulfilled fulfilled
   Criteria of NMO fulfilled not fulfilled
ANA = antinuclear antibody; MBP = myelin basic protein; NMO = neuromyelitis optica; SjS = Sjögr
* including first attack
Patient
ren's Syndrome
